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Background: Despite positive results from large phase III clinical trials proved that it is possible to prevent
estrogen-responsive breast cancers with selective estrogen receptor modulators and aromatase inhibitors, no
significant results have been reached so far to prevent hormone non-responsive tumors. The Ductal Lavage (DL)
procedure offers a minimally invasive method to obtain breast epithelial cells from the ductal system for
cytopathologic analysis. Several studies with long-term follow-up have shown that women with atypical hyperplasia
have an elevated risk of developing breast cancer. The objective of the proposed trial is to assess the efficacy and
safety of a daily administration of nimesulide or simvastatin in women at higher risk for breast cancer, focused
particularly on hormone non-responsive tumor risk. The primary endpoint is the change in prevalence of atypical
cells and cell proliferation (measured by Ki67) in DL or fine needle aspirate samples, after 12 months of treatment
and 12 months after treatment cessation.
Methods-Design: From 2005 to 2011, 150 women with a history of estrogen receptor negative ductal
intraepithelial neoplasia or lobular intraepithelial neoplasia or atypical hyperplasia, or unaffected subjects carrying a
mutation of BRCA1 or with a probability of mutation >10% (according to BRCAPRO) were randomized to receive
nimesulide 100mg/day versus simvastatin 20mg/day versus placebo for one year followed by a second year of
follow-up.
Discussion: This is the first randomized placebo controlled trial to evaluate the role of DL to study surrogate
endpoints biomarkers and the effects of these drugs on breast carcinogenesis. In 2007 the European Medicines
Agency limited the use of systemic formulations of nimesulide to 15 days. According to the European Institute of
Oncology Ethics Committee communication, we are now performing an even more careful monitoring of the study
participants. Preliminary results showed that DL is a feasible procedure, the treatment is well tolerated and the
safety blood tests do not show any significant liver toxicity. There is an urgent need to confirm in the clinical
setting the potential efficacy of other compounds in contrasting hormone non-responsive breast cancer. This paper
is focused on the methodology and operational aspects of the clinical trial.
Trial Registration: (ClinicalTrials.gov Identifier: NCT01500577)
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Breast cancer (BC) is now the most common cancer
diagnosed in women worldwide and is the leading cause
of deaths from cancer among women [1]. Recently BC
prevention has been greatly improved and the chemo-
preventive efficacy of various compounds, particularly
Selective Estrogen Receptor Modulators (SERMs) and
more recently aromatase inhibitors (AIs), has been re-
peatedly documented. However these drugs have shown
to be effective almost exclusively in hormone-responsive
(ER positive) BCs. At least one-third of BCs will not be
influenced by hormonal interventions because of the ab-
sence of ER expression since the beginning and another
number of cancers will subsequently “escape” the hor-
monal control and become resistant to tamoxifen and
AIs. Unfortunately, ER negativity is frequently combined
with other characteristics of biological aggressiveness
(high grade and proliferation, overexpression of HER2/
neu), resulting in a worse prognosis [2,3]. Furthermore,
women with a family history of breast and ovarian can-
cer have a higher risk of developing ER negative BC
compared with the general population. In particular
BRCA-1 mutation carriers have approximately 90% ER
negative tumours, and display a characteristic gene ex-
pression profile [4]. For all these reasons, methods to
better select subjects at higher risk for ER negative BC
and strategies to prevent it are actively being sought.
Several studies with long-term follow-up have shown
that women with atypical hyperplasia have an elevated
risk of developing breast cancer [5-8].
The ductal lavage (DL) procedure offers a minimally
invasive method to obtain breast epithelial cells from the
ductal system for cytopathologic analysis to provide indi-
vidualized risk assessment with a sensitivity up to 3.2
times greater than that of Nipple Aspirate Fluid (NAF)
in detecting abnormal intraductal cells [9].
Over-expression of cyclooxygenase-2 (COX-2) has
been detected in a variety of human tumors in breast,
prostate, lung, skin, and colon [10]. Nimesulide, a prefer-
ential COX-2 inhibitor, has been used clinically as an
anti-inflammatory agent in Europe, Asia and Africa.
COX-2 inhibition by nimesulide has been shown to in-
hibit cancer cell proliferation and induce cancer cell
apoptosis in vitro [11,12], and prevent tumor growth
and metastasis in vivo [13-15]. However, COX-2/PGE2-
independent mechanisms have also been reported to
mediate the anti-tumor activity of nimesulide [16,17].
Statins (HMG-CoA reductase inhibitors), the most
widely used medications in the western world to manage
hypercholesterolemia and associated morbidities [18],
may affect the occurrence or outcomes of other diseases
—including cancer—either by downstream consequences
of cholesterol reduction or by mechanisms outside of
the cholesterol synthesis pathway [19,20]. A recentmetanalisis showed that Simvastatin, a highly lipophilic
statin, was associated with a reduced risk of breast can-
cer recurrence among Danish women diagnosed with
stage I–III breast carcinoma, whereas no association be-
tween hydrophilic statin use and breast cancer recur-
rence was observed [21].
All these data, together with the long post-marketing
surveillance of both compounds, make these two drugs
most interesting to investigate in a chemoprevention trial
in subjects at higher risk for ER negative breast cancer.
We are conducting a phase II, randomized, double
blind, placebo controlled trial in 150 women at increased
risk for hormone non-responsive breast cancer, randomly
assigned to receive nimesulide 100 mg or simvastatin 20
mg once daily or matching placebo for 12 months, and
then followed for another year. This paper describes the
rationale and design of the study, thus focusing on the
methodology and operational aspects of the clinical trial.
Methods
Ethical considerations and registration
The study protocol is in compliance with the Declaration of
Helsinki [22]. We obtained approval for this study from the
Ethics committee of the European Institute of Oncology on
February 3rd 2005 (EUDRACT N.: 2004-005267-21). The
protocol and informed consent forms were approved by the
institutional ethics committee at each of the participating
institutions. The trial has been registered with the Clinical-
Trials.gov Identifier: NCT01500577. Written informed con-
sent for participation in the study has been obtained from
all the participating patients.
Design overview
We are conducting a monoistitutional phase II, rando-
mized, double blind, placebo controlled trial to assess
the efficacy and the safety of a daily administration of
nimesulide or simvastatin to change the expression of a
large set of tissue and circulating surrogate endpoint
biomarkers (SEBs) of breast carcinogenesis in women at
higher risk of developing a hormone non-responsive (ER
negative) breast cancer. The primary endpoint is the
change in prevalence of atypical cells and cell prolifera-
tion (Ki-67), after 12 months of treatment. A total of
150 women were randomized: 50 per arm. Within the 3
treatment groups, subjects were stratified according to
their hormonal status (premenopausal vs. postmenopau-
sal ) and Ductal Intraepithelial Neoplasia (DIN)/Lobular
Intraepithelial Neoplasia (LIN)/Atypical Hyperplasia
(AH) vs. High genetic risk and centre. A schema of the
trial design is presented in Figure 1.
Participants selection
Eligible subjects are women at increased risk for hor-
mone non-responsive BC: patients with previous surgery
Figure 1 Trial design.
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affected subjects carrying a mutation of BRCA1 or with
high probability of BRCA1/2 mutation. This represents a
relatively heterogeneous group with various degrees of
risk, but all characterized by a higher probability to de-
velop a ER negative breast cancer rather than other
cohorts of subjects. Their risk is often confirmed by a
diagnosis of IEN at young age and/or by an early germ-
line mutation assessment. Moreover, no current prevent-
ive treatments (especially endocrine) could be reasonably
proposed to most of these subjects.
– Patients with ER negative DIN (within 12 months
from radical surgery)
– Patients with AH (within 12 months from radical
surgery)
– Patients with LIN (within 12 months from radical
surgery)
– Unaffected carriers of BRCA1 mutation– Unaffected subjects with high probability of BRCA1/
2 gene mutation (≥ 10 % according to Berry
Parmigiani and/or Couch model).
On the basis of a weekly multidisciplinary meeting
the candidates are contacted by phone by trained
personnel illustrating the possibility of taking part in a
chemoprevention trial and scheduling an appointment
for an outpatient visit at the European Institute of On-
cology. In case of a previous diagnosis of IEN,
randomization is performed within 12 months from
surgery. Inclusion and exclusion criteria are summar-
ized in Figure 2.
Recruitment and retention strategy
Pre-initiation phase
Subjects with a previous surgery of ER negative IEN, and
unaffected subjects carrying a mutation of BRCA1 or
Figure 2 Inclusion and exclusion criteria.
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tentially eligible for the trial are addressed to the oncolo-
gist and the geneticist respectively.
Active recruitment
After the evaluation by the oncologist of the multidis-
ciplinary team, patients surgically treated for IEN re-
ceive a Hospital Discharge Report including an
appointment to discuss the trial and, when possible,
the alternative options. Unaffected subjects carrying a
mutation of BRCA1 or with high probability ofBRCA1/2 mutation on the basis of the geneticist
evaluation are contacted by the staff of the Division of
Cancer Prevention and Genetics for a first phone
interview and the check of all inclusion criteria. The
trial design is explained and willingness to participate
is asked. Candidates accepting to participate or inter-
ested in the study are invited for a clinic visit at the
European Institute of Oncology (EIO) or the Depart-
ment of Oncology & Haematology of the University of
Modena and Reggio Emilia for informed consent and
baseline visit.
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Subjects are scheduled for periodic visits (every 3
months in the first year) during which a complete phys-
ical exam and lab tests are performed. A couple of weeks
before the following scheduled appointment, participants
are reminded about the visit, blood test and physical
exam. Recruitment and retention effort are evaluated
routinely by the site coordinator and the study staff.Treatment groups
Patients who signed an informed consent and who met
the eligibility criteria are randomly assigned to one of
three groups for 12 months of treatment, as follows.
Group 1: nimesulide 100 mg/day, administered per os
and on full stomach. A single oral dose of 100 mg of
nimesulide suppresses COX-2 activity by 90% in both
in vitro and ex vivo assays and, at a much lesser extent,
COX-1 activity with a 20-fold selectivity for the former
isoenzyme [23]. This dose is half the standard dose to
obtain a faster effect on pain control and inflammation,
but it may represent an active and safer dose for testing
the chemopreventive efficacy of nimesulide. Moreover,
this dose is able to reach a plasma concentration of 2–4
μg/ml [23], which is more than 10 times the IC50 neces-
sary for the inhibition of COX-2 activity in blood assays,
whereas it is five times lower than the IC50 for COX-1
inhibition [24]. Therefore, 100 mg/day appears a reason-
able dose for chemopreventive purposes implying pro-
longed administration.
On May 15, 2007 the Irish Medicines Board (IMB)
decided to suspend nimesulide from the Irish market
and refer it to the EU Committee for Human Medicinal
Products (CHMP) for a review of its benefit/risk profile.
The decision was due to the reporting of six cases of
potentially related liver failures to the IMB by the
National Liver Transplant Unit, St Vincent Hospital.
These cases occurred in the period from 1999 to 2006.
On September 21, 2007 the EMA released a press re-
lease on their review on the liver-related safety of nime-
sulide. The EMA concluded that the benefits of these
medicines outweigh their risks, but that there was a need
to limit the duration of use to ensure the risk of patients
developing liver problems is kept to a minimum. There-
fore the EMA has limited the use of systemic formula-
tions of nimesulide to 15 days. According to the
European Institute of Oncology Ethics Committee com-
munication, released officially on October 10, 2007
which recommended the maintenance of the study
according to the present design, we are now performing
an even more careful monitoring of the study partici-
pants and we are carrying out a systematic check of the
possible side effects, both in those who are receiving
treatment and in those who have finished. We havemodified the Inform consent and we have informed all
the participants accordingly.
Group 2: simvastatin 20 mg/day. The most important
adverse events associated with statins are asymptomatic
increases in liver transaminases, and myopathy. Myop-
athy and its serious complication, rhabdomyolysis, are
potential side effects of therapy with the available statins,
but occur very rarely. The molecular and biochemical
mechanisms of myopathy and rhabdomyolysis caused by
statins are yet to be fully elucidated [25]. However, a
compilation of all randomized statin trials revealed that
among 83,858 patients randomly assigned to receive ei-
ther statin treatment or placebo, there were only 49
cases of myositis and 7 cases of rhabdomyolysis in the
statin groups, compared with 44 cases of myositis and 5
cases of rhabdomyolysis in the placebo groups [26].
Group 3: placebo. An identical appearing tablet con-
taining placebo is taken daily by participants assigned to
the placebo group.
Toxicity is evaluated at each visit using the NCI tox-
icity criteria (CTCAE version 3.0, published 12/12/03).
Any use of systemic drugs is clearly documented (time,
doses, routes, and indications) and strictly followed by
the physician. All medications (prescription and over-the
counter), vitamin and mineral supplements, and/or
herbs taken by the participant are documented on the
concomitant medication CRF and included: start and
stop date, dose and route of administration, and indica-
tion for use. Medications taken for a procedure (e.g., bi-
opsy) are included. Patients are discouraged from taking
unspecified medications.
Adherence/compliance to treatment
Although drug concentration is not being measured in
the blood, compliance is monitored in the following
ways.
Patient self-report
Patient's history—the most direct source of information
—is the most widely employed measure of a patient's ad-
herence to their medical regimen. However, patient self-
reporting has been criticized as being too subjective,
with patients tending to over-report their adherence by
as much as two to fourfold. Positive information is help-
ful, but false negatives are common.
Calendar completion
Each subject is given a 7-month calendar as a reminder
of drug consumption. Each subject is asked to cross the
corresponding day of the calendar (1 cross for each con-
sumption). Subjects are asked to fill the calendar and
some additional space is left for patient's notes. Each cal-
endar is returned at the next scheduled visit.
Table 1 Follow-up procedures and main outcome
measures
Month




Mammography X X X
Breast Ultrasound (if indicated) X X X
Physical examination X X X X X X
Ductal Lavage (or FNA) X X X
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Each subject receives a 6-month supply (at baseline and
6th month visits) of the drug or placebo and they are
asked to return all full and empty packs, irrespective of
their use. Pills are counted and the compliance is mea-
sured as follows: number of pills taken (i.e., number of
pills given-number of pills returned)/number of pills that
should have been taken during that period of time. If
packs are not returned, the compliance is calculated
from the calendar. In case of discrepancy between the
pill counts and the calendar, pill count is taken as the
superseding compliance measure.Concomitant medication X X X X X X
AE/ADR (*) X X X X X X
Hematology/biochemistry X X X X X X
Hormones, IGFs, SHBG, C-Reactive Protein X X X
(*) AE/ADR, adverse event/adverse drug reaction.Clinical evaluation and procedures
Date of birth, occupation, complete address and phone
number, full details of family doctor; previous medical
history; general physical examination, including an-
thropometric features; first or second degree family his-
tory of cancer; number of pack-years of cigarettes;
alcohol consumption; concomitant medications.
Participants are assessed at baseline, 3, 6, 9, 12 and 24
months with clinical examination and blood safety tests.
Mammography are performed at baseline, 12 and 24
months. DL are performed at baseline, 12 and 24
months in all subjects. In case of anatomical impedi-
ments to perform DL, this is substituted by a breast fine
needle aspiration (FNA), preferably ultrasound-guided in
the most dense area of the breast. Breast ultrasound is
performed in premenopausal women at baseline, 12 and
24 months, in postmenopausal only if indicated by the
study physician. Blood drawing for biomarkers and hor-
mone measurements are done at baseline, 12 and 24
months. Intervention with nimesulide or simvastatin or
placebo continues for 12 months or until the occurrence
of a serious adverse event, including breast cancer. A
detailed follow-up schema is illustrated in Table 1.Methods for ductal lavage and fine needle aspiration
DL is performed by a single physician for both recruiting
centers with a dedicated microcatheter (Sterylab, Rho,
Italy) to cannulate ductal orifices on the nipple that are
identified by nipple discharge. After the duct has been
cannulated, and a small infusion of local anesthesia is
performed, the milk duct is infused with a saline solu-
tion. DL is performed in the contralateral breast in DIN/
LIN/AH patients and bilaterally in healthy high risk sub-
jects or in DIN/LIN/AH patients when feasible. The
fluid collected from the effluent tube is then analyzed
for the presence of cell alterations. Ki-67 expression in
epithelial cells obtained by DL is calculated using the
percentage of cells expressing the antigen over the total
number of epithelial cells. The localization of the cannu-
lated duct is recorded on a specific nipple grid in orderto collect samples always from the same breast duct
(Figure 3).
In case of anatomical impediments to perform DL, this
is substituted by a breast FNA, preferably ultrasound-
guided in the most dense area of the breast. In all sam-
ples obtained by FNA, ER, PgR, and Ki-67 are analyzed
using the immunohistochemical (IHC) method. Ki-67 is
expressed as the actual percentage of stained cells over a
total of at least 2000 tumor cells at high magnification
(400 x).
Methods for biomarker measurements
Fasting blood samples for circulating biomarkers are col-
lected and stored at −80°C until assayed. All the circulat-
ing biomarkers are determined on serum. IGF-I and
prolactin are measured by a chemiluminescent immuno-
metric assay (Nichols Institute Diagnostics, San Juan,
CA). The assays are performed on the automatic instru-
ment LIAISON (DiaSorin Deutschland GmbH, Dietzen-
bach, Germany). IGFBP-1 is measured by a two-site
immunoradiometric assay, IGFBP-2 by a double-
antibody radioimmunoassay (RIA) and IGFBP-3 by
enzyme-linked immunosorbent assay, all provided by
Diagnostic Systems Laboratories Inc. (Webster, TX).
IGF-I and IGFBP concentrations are expressed in nano-
molar (nmol) concentrations to calculate the IGF-I/
IGFBP ratio, which is used as a more sensitive index of
growth factor bioavailability. SHBG and C-reactive pro-
tein are determined by a chemiluminescent immuno-
metric assay provided by Diagnostic Products
Corporation, Inc. (Los Angeles, CA) designed for the
Immulite Automated analyzer. Estradiol is measured by
a 3rd generation RIA provided by Diagnostic System La-
boratories Inc. (Webster, TX). Estrone-sulphate and
Dehydroepiandrosterone-sulphate are determined by
Figure 3 Ductal Lavage. a | saline is injected through the catheter into the duct and the breast is massaged to bring ductal cells into the
chamber of the catheter. An empty syringe attached to the catheter is used to collect the cells from the catheter chamber. Saline injection and
massage are repeated until a sufficient sample has been collected. b | microcatheter. c | nipple grid. d | Examples of ductal epithelial cells
collected by ductal lavage: i) ductal hyperplasia; ii) atypical ductal hyperplasia; iii) ki-67 expression.
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Inc. (Webster, TX). Pre- and post-treatment blood sam-
ples obtained from each subject are assayed within the
same run to improve analytical precision. All analyses
are blinded to the treatment groups.
Toxicity and dose modification
Toxicity is evaluated at each visit using the NCI com-
mon terminology criteria for adverse events (CTCAE,
version 3.0, revised June 10, 2003 http://ctep.cancer.gov).
If grade 1 toxicity occurs, the participant is maintained
on full doses. Toxicity is checked depending on clinical
relevance but at least within 3 months by telephone or
clinical visit. Grade 2 adverse events is monitored and
treated depending on clinical relevance but at least
within 3 months by clinical visit. If grade 2 toxicityshould occur, treatment may not be stopped but reduced
at 50% of the dose for 1 month and symptomatic relief
is started. If grade 2 toxicity does not improve at all after
1 month at half dose (i.e. capsule taken on alternate
days), treatment is stopped; otherwise it may be restored
at full dose. For grade 3 or 4 toxicity, subjects come off




A total of 150 subjects are allocated in the three treat-
ment groups: 50 for each treatment group. Within the 3
treatment groups, subjects are stratified according to
their hormonal status (premenopausal vs. postmenopau-
sal), DIN/LIN/AH vs. Genetic High Risk, and centre.
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duction from an anticipated 50% 12-month prevalence
of atypical hyperplasia and cellular proliferation (Ki-67)
in the control arm to 25% in each of the treated arms.
The specification of an alpha level of 0.1 and a one-sided
test were used in the calculation of the power. Both
choices of an alpha level greater than 0.05 and a one-
sided test are justifiable in phase II studies, also consid-
ering that the study is interested in determining if the
prevalence of atypical hyperplasia and cellular prolifera-
tion (Ki-67) is reduced by the investigated treatments.
The planned sample size incorporates a correction for
possibly inadequate tissue sampling in about 20% of
study subjects.
Statistical methods
Each of the two active treatment groups will be com-
pared separately with the control group for 12-month
prevalence of atypical hyperplasia and cellular prolifera-
tion (Ki-67), considered as two distinct endpoints. The
comparison will be based on Pearson’s Chi-square test.
A secondary analysis will be carried out within a Gener-
alized Estimating Equations (GEE) logistic regression
modeling approach. Such analysis will incorporate base-
line and 12-month measurements, and will take into ac-
count possible correlation between the two assessments
made within the same subject. Secondary endpoints con-
sidered in this study are represented by continuous vari-
ables. Treatment effect on their change over time will be
investigated by means of covariance analysis (ANCOVA),
possibly after suitable data transformations to achieve
normal distributions.
Randomisation
A randomization list is prepared using permuted blocks
to ensure that an equal number of subjects are assigned
to the 3 arms at different points of the randomization
process. Neither the investigators involved with the
study nor the women participating know which type of
preparation is administered. The treatment and pertin-
ent arm to which a patient has been allocated is made
known only in the case of proven need (e.g., severe ad-
verse events) by the Data Center upon formal written
authorization of the Principal Investigator.
Blinding
All participants, those who administer the therapy and
those who assess the outcomes are blinded to group as-
signment to ensure the double blind design. Both nime-
sulide and simvastatin have been purchased from the
market, placebo capsules have been prepared by the
Hospital Pharmacy of the European Institute of Oncol-
ogy (EIO). All the treatments are blinded by over-
encapsulation and appear as capsules (size 0) of thesame colour and exactly identical. Drug or placebo are
provided in boxes (of identical shape) containing the
capsules needed for each semester. They are manufac-
tured by the EIO pharmacy. The code will be revealed to
researchers and participant once recruitment, data col-
lection, and laboratory analyses are complete.
Recruitment and preliminary results
Among the 528 women evaluated for protocol inclusion,
388 were eligible according to inclusion criteria charac-
teristics. The flow diagram of study of the randomized
trial is shown in Figure 4. The accrual phase ended in
2011, with the randomization of the planned 150 sub-
jects: 68 ER negative DIN, 50 LIN and AH and 32 sub-
jects with BRCA1 mutation or high mutation
probability. So far 125 women have completed the study.
Ductal lavage has shown to be a feasible and reprodu-
cible procedure (only 7 patients who underwent DL at
baseline shifted to FNA at 12 months). The treatment is
very well tolerated and the safety blood tests did not
show any significant liver toxicity, only few grade 1 for
one of the liver enzymes. Only few subjects had CPK al-
teration with grade 1 toxicity. One case was included in
the study with a baseline level of CPK grade 2 by mis-
take and the patient was withdrawn from the study. In-
cluding this last case, five subjects dropped out: two for
gastrointestinal symptoms, one for muscle ache, and one
refused to continue.
Discussion
The success of chemopreventive approach depends on
the recognition of high-risk subjects, the development of
novel and safe agents, and the identification of new sur-
rogate endpoint biomarkers using molecular pathways
and new targets of drugs activity. Several chemopreven-
tion studies have demonstrated that it is possible to re-
duce the incidence of hormone receptor positive breast
cancer and that chemoprevention is clinically safe and
well tolerated. Unfortunately we have no effective
agents to prevent ER-negative breast cancer which
accounts for 20–30% of breast cancers and has a poor
prognosis [27]. Thus, it is worth identifying biomarkers
and agents that are effective in the treatment and pre-
vention of these subtypes. Several classes of new agents
modulating the non-endocrine biochemical pathways
have been developed and many of these are still cur-
rently under investigation. These agents include reti-
noids, epidermal growth factor receptor (EGFR),
tyrosine kinase inhibitors (TKIs), cyclooxygenase-2
(COX-2) inhibitors, bisphosphonates, vitamin D receptor
(VDR), statins, peroxisome proliferator activated recep-
tor (PPAR), and others [28]. Safety is a major issue to
take into account, since large randomized chemo-
prevention trials have shown that few serious adverse
Figure 4 Number of subject for each phase of the randomized trial.
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ventive agents despite their proven efficacy. Our prelim-
inary results showed that the treatment is very well
tolerated and the safety blood tests did not show any sig-
nificant liver toxicity. Ductal lavage has been proposed
as a minimally-invasive, well-tolerated tool for obtaining
breast epithelial cells for cytological evaluation of breast
cancer risk. However, our trial might have some limita-
tions. Ductal lavage can be highly time consuming,
restricting its utility as a high-throughput clinical
method. Furthermore, the effluent lavage fluid is highly
diluted, thus potentially limiting its utility in possible fu-
ture biochemical analysis. In spite of consistent data on
Ki67 as a prognostic marker in early breast cancer, its
role in atypical cells is uncertain. Furthermore, thevariation in analytical practice markedly limits the value
of Ki67 in this context. We assume to start the analysis
of the primary and secondary endpoints within a year.
To our knowledge, this is the first randomized placebo
controlled trial to evaluate the role of ductal lavage to
study surrogate endpoints biomarkers and the effects of
these drugs on breast carcinogenesis.
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